Rekombinanter RSV (Palivizumab Biosimilar) Antikörper

Produktnummer ABIN7200664

Dieses Anti-RSV (Palivizumab Biosimilar)-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von RSV (Palivizumab Biosimilar) in FACS und in vivo. Geeignet für Human.

Kurzübersicht für Rekombinanter RSV (Palivizumab Biosimilar) Antikörper (ABIN7200664)

Target: RSV (Palivizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser RSV (Palivizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Produktdetails anti-RSV (Palivizumab Biosimilar) Antikörper

Verwendungszweck: Palivizumab Biosimilar, RSV Monoclonal Antibody

Spezifität: The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).

Produktmerkmale: Recombinant Humanized IgG1 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu RSV (Palivizumab Biosimilar)

Target: RSV (Palivizumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.